BR112022016220A2 - Polipeptídeos, composições e seu uso para tratar ou limitar o desenvolvimento de uma infecção - Google Patents
Polipeptídeos, composições e seu uso para tratar ou limitar o desenvolvimento de uma infecçãoInfo
- Publication number
- BR112022016220A2 BR112022016220A2 BR112022016220A BR112022016220A BR112022016220A2 BR 112022016220 A2 BR112022016220 A2 BR 112022016220A2 BR 112022016220 A BR112022016220 A BR 112022016220A BR 112022016220 A BR112022016220 A BR 112022016220A BR 112022016220 A2 BR112022016220 A2 BR 112022016220A2
- Authority
- BR
- Brazil
- Prior art keywords
- polypeptides
- infection
- treat
- development
- limit
- Prior art date
Links
- 208000015181 infectious disease Diseases 0.000 title abstract 3
- 239000000203 mixture Substances 0.000 title abstract 3
- 229920001184 polypeptide Polymers 0.000 title abstract 3
- 102000004196 processed proteins & peptides Human genes 0.000 title abstract 3
- 108090000765 processed proteins & peptides Proteins 0.000 title abstract 3
- 125000003275 alpha amino acid group Chemical group 0.000 abstract 2
- 239000002105 nanoparticle Substances 0.000 abstract 2
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
- A61K39/215—Coronaviridae, e.g. avian infectious bronchitis virus
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55511—Organic adjuvants
- A61K2039/55555—Liposomes; Vesicles, e.g. nanoparticles; Spheres, e.g. nanospheres; Polymers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/57—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
- A61K2039/575—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2 humoral response
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
- C12N2770/00011—Details
- C12N2770/20011—Coronaviridae
- C12N2770/20022—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
- C12N2770/00011—Details
- C12N2770/20011—Coronaviridae
- C12N2770/20034—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Virology (AREA)
- General Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Molecular Biology (AREA)
- Public Health (AREA)
- Communicable Diseases (AREA)
- General Chemical & Material Sciences (AREA)
- Microbiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Genetics & Genomics (AREA)
- Biophysics (AREA)
- Biochemistry (AREA)
- Gastroenterology & Hepatology (AREA)
- Epidemiology (AREA)
- Immunology (AREA)
- Oncology (AREA)
- Mycology (AREA)
- Pulmonology (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Applications Claiming Priority (4)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202062977036P | 2020-02-14 | 2020-02-14 | |
| US202063046159P | 2020-06-30 | 2020-06-30 | |
| US202063064235P | 2020-08-11 | 2020-08-11 | |
| PCT/US2021/017799 WO2021163438A1 (en) | 2020-02-14 | 2021-02-12 | Polypeptides, compositions, and their use to treat or limit development of an infection |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| BR112022016220A2 true BR112022016220A2 (pt) | 2022-10-25 |
Family
ID=74873805
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| BR112022016220A BR112022016220A2 (pt) | 2020-02-14 | 2021-02-12 | Polipeptídeos, composições e seu uso para tratar ou limitar o desenvolvimento de uma infecção |
Country Status (13)
| Country | Link |
|---|---|
| US (1) | US20240277831A1 (https=) |
| EP (1) | EP4103230A1 (https=) |
| JP (1) | JP2023513720A (https=) |
| KR (1) | KR20220142472A (https=) |
| CN (1) | CN116096404A (https=) |
| AU (1) | AU2021221139A1 (https=) |
| BR (1) | BR112022016220A2 (https=) |
| CA (1) | CA3167318A1 (https=) |
| CO (1) | CO2022011467A2 (https=) |
| MX (1) | MX2022009860A (https=) |
| PE (1) | PE20230301A1 (https=) |
| PH (1) | PH12022552099A1 (https=) |
| WO (1) | WO2021163438A1 (https=) |
Families Citing this family (18)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US12194089B2 (en) | 2020-02-04 | 2025-01-14 | CureVac SE | Coronavirus vaccine |
| US11241493B2 (en) | 2020-02-04 | 2022-02-08 | Curevac Ag | Coronavirus vaccine |
| JP2023521418A (ja) | 2020-04-10 | 2023-05-24 | インビビド， インコーポレイテッド | コロナウイルスｓタンパク質に特異的な化合物及びその使用 |
| WO2022016122A2 (en) * | 2020-07-17 | 2022-01-20 | Tonix Pharmaceuticals Holding Corp. | Skin-based testing for detection of cell-mediated immune responses to sars-cov-2 |
| US11918643B2 (en) | 2020-12-22 | 2024-03-05 | CureVac SE | RNA vaccine against SARS-CoV-2 variants |
| US20220324918A1 (en) * | 2021-03-30 | 2022-10-13 | Regents Of The University Of Minnesota | SARS-CoV-2 SPIKE ECTODOMAIN POLYPEPTIDES AND COMPOSITIONS AND METHODS THEREOF |
| WO2023034991A1 (en) * | 2021-09-02 | 2023-03-09 | Kansas State University Research Foundation | Mrna vaccine formulations and methods of using the same |
| US20240385189A1 (en) * | 2021-09-10 | 2024-11-21 | Jacobs Technion-Cornell Institute | Compositions and methods for determining humoral immune responses against seasonal coronaviruses and predicting efficiency of sars-cov-2 spike targeting, covid-19 disease severity, and providing interventions |
| KR102527221B1 (ko) * | 2021-10-15 | 2023-05-02 | 에스케이바이오사이언스 주식회사 | 단백질의 정제방법 |
| KR102621026B1 (ko) * | 2021-10-15 | 2024-01-09 | 에스케이바이오사이언스(주) | 단백질의 정제방법 |
| KR102524839B1 (ko) * | 2021-11-04 | 2023-04-25 | 에스케이바이오사이언스(주) | 사스-코로나바이러스-2 감염증 예방 또는 치료용 백신 조성물 |
| US20250000968A1 (en) * | 2021-11-12 | 2025-01-02 | The United States of America, as represented by the Secretary,Department of Health and Human Service | Sars-cov-2 spike fused to a hepatitis b surface antigen |
| WO2023122257A2 (en) * | 2021-12-22 | 2023-06-29 | La Jolla Institute For Immunology | Coronavirus spike glycoprotein with improved expression and stability |
| CN114656571B (zh) * | 2022-02-18 | 2024-07-16 | 中山大学肿瘤防治中心（中山大学附属肿瘤医院、中山大学肿瘤研究所） | 一种四价SARS-CoV-2嵌合纳米颗粒疫苗及其制备方法与应用 |
| US20240207389A1 (en) * | 2022-04-27 | 2024-06-27 | Northwestern University | Methods for improving covid vaccine immunogenicity |
| WO2024014943A1 (ko) * | 2022-07-12 | 2024-01-18 | 에스케이바이오사이언스 주식회사 | Sars-cov-2 백신 부스터 조성물 |
| WO2024076982A2 (en) * | 2022-10-05 | 2024-04-11 | University Of Washington | Pan-sarbecovirus nanoparticle vaccines |
| EP4608442A1 (en) | 2022-10-28 | 2025-09-03 | GlaxoSmithKline Biologicals S.A. | Nucleic acid based vaccine |
Family Cites Families (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EA017887B1 (ru) * | 2007-08-02 | 2013-03-29 | Байондвакс Фармасьютикалз Лтд. | Полимерные мультиэпитопные вакцины против гриппа |
| US10248758B2 (en) * | 2013-02-07 | 2019-04-02 | University Of Washington Through Its Center For Commercialization | Self-assembling protein nanostructures |
| CN105934441A (zh) * | 2013-11-26 | 2016-09-07 | 贝勒医学院 | 新型sars免疫原性组合物 |
| US9630994B2 (en) * | 2014-11-03 | 2017-04-25 | University Of Washington | Polypeptides for use in self-assembling protein nanostructures |
| US10676511B2 (en) * | 2015-09-17 | 2020-06-09 | Ramot At Tel-Aviv University Ltd. | Coronaviruses epitope-based vaccines |
| WO2018175560A1 (en) * | 2017-03-22 | 2018-09-27 | The Scripps Research Institute | Nanoparticle immunogens to elicit responses against the influenza receptor binding site on the hemagglutinin head domain |
| HUE073526T2 (hu) * | 2017-04-04 | 2026-01-28 | Univ Washington | Önmagát összeállító fehérje nanostruktúrák, amelyek paramyxovírus és/vagy pneumovírus F fehérjéket jelenítenek meg és azok használata |
| WO2019169120A1 (en) * | 2018-02-28 | 2019-09-06 | University Of Washington | Self-asssembling nanostructure vaccines |
-
2021
- 2021-02-12 WO PCT/US2021/017799 patent/WO2021163438A1/en not_active Ceased
- 2021-02-12 AU AU2021221139A patent/AU2021221139A1/en active Pending
- 2021-02-12 PE PE2022001743A patent/PE20230301A1/es unknown
- 2021-02-12 CA CA3167318A patent/CA3167318A1/en active Pending
- 2021-02-12 BR BR112022016220A patent/BR112022016220A2/pt unknown
- 2021-02-12 MX MX2022009860A patent/MX2022009860A/es unknown
- 2021-02-12 KR KR1020227031351A patent/KR20220142472A/ko active Pending
- 2021-02-12 CN CN202180028727.9A patent/CN116096404A/zh active Pending
- 2021-02-12 US US17/760,174 patent/US20240277831A1/en active Pending
- 2021-02-12 EP EP21711980.9A patent/EP4103230A1/en active Pending
- 2021-02-12 PH PH1/2022/552099A patent/PH12022552099A1/en unknown
- 2021-02-12 JP JP2022548783A patent/JP2023513720A/ja active Pending
-
2022
- 2022-08-16 CO CONC2022/0011467A patent/CO2022011467A2/es unknown
Also Published As
| Publication number | Publication date |
|---|---|
| PH12022552099A1 (en) | 2024-01-29 |
| CA3167318A1 (en) | 2021-08-19 |
| MX2022009860A (es) | 2022-11-07 |
| US20240277831A1 (en) | 2024-08-22 |
| EP4103230A1 (en) | 2022-12-21 |
| AU2021221139A1 (en) | 2022-09-01 |
| PE20230301A1 (es) | 2023-02-13 |
| KR20220142472A (ko) | 2022-10-21 |
| CO2022011467A2 (es) | 2022-10-31 |
| CN116096404A (zh) | 2023-05-09 |
| JP2023513720A (ja) | 2023-04-03 |
| WO2021163438A1 (en) | 2021-08-19 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| BR112022016220A2 (pt) | Polipeptídeos, composições e seu uso para tratar ou limitar o desenvolvimento de uma infecção | |
| MX2020004578A (es) | Composiciones de casz y metodos de uso. | |
| PT1548032E (pt) | Péptidos kdr e vacinas que os contêm | |
| BR0209689A (pt) | Uso de fragmento de hmg como agente anti-inflamatório | |
| CL2018000537A1 (es) | Anticuerpo anti-factor d del complemento; polinucleótido codificante; vector que comprende dicho polinucleótido; célula húesped que comprende dicho vector; método de fabricación de anticuerpo; composición farmacéutica que lo comprende; uso del anticuerpo para tratar trastornos inflamatorios o trastornos oculares (divisional de cl 1001-2009). | |
| BRPI0414313A (pt) | inibidores de citocinas | |
| BR112017023380A2 (pt) | sistema, composição cosmética, métodos para tratamento de substratos queratinosos e para proteção e/ou alisamento da fibra do cabelo, kit multicompartimento, e, processo para alisamento do cabelo. | |
| BR112022001657A2 (pt) | Polipeptídeo de fusão, sequência de ácidos nucleicos, cassete de expressão, vetor de expressão, célula hospedeira, composição farmacêutica, e, métodos para tratar a ataxia de friedreich e para tratar uma doença associada à ataxia de friedreich | |
| BR9808772A (pt) | Composição de vacina multivalente com carreadora misturada | |
| AR008588A1 (es) | Molecula de acido nucleico aislada que hibridiza con un gen de saliva de pulga, proteina aislada codificada por dicha molecula, composicion terapeuticapara tratar la dermatitis alergica, kit de ensayo para determinar dicha dermatitis, molecula, virus y celula recombinantes, y anticuerpo aislado | |
| BR0012919A (pt) | Vacina para uso na profilaxia e/ou no tratamento da sìndrome de ponto branco (white spot syndrome) em crustáceos, proteìna estrutural derivada do vìrus da sìndrome de ponto branco, sequência de ácido nucléico, uso de uma proteìna estrutural, composição farmacêutica, anticorpos, vacina ou formulação farmacêutica, e, kit diagnóstico para detecção de wssv | |
| JOP20210013A1 (ar) | تركيبات جسم مضاد fcrn | |
| BR112022008201A2 (pt) | Degradação de proteínas de superfície usando agente de ligação biespecífico | |
| BR112022018254A2 (pt) | Anticorpos isolados, ácido nucleico isolado, vetor ou conjunto de vetores, célula hospedeira, métodos para produzir um anticorpo, para tratar um distúrbio e para tratar ag em um paciente, composição e uso de um anticorpo | |
| MX2024000901A (es) | Composiciones y metodos para la degradacion selectiva de proteinas dise?adas por ingenieria. | |
| EA202190310A1 (ru) | Белок для лечения воспалительных заболеваний | |
| BR112022023506A2 (pt) | Composto, composição farmacêutica, uso do composto e método de uso de um composto | |
| CL2024001482A1 (es) | Péptido con afinidad por el receptor de transferrina humana | |
| BR112022004563A2 (pt) | Coliberação de sirna tgf-ß e sirna pdl1 para tratar câncer | |
| BR112012011598A2 (pt) | polipeptídeos de haemophilus parasuis e métodos de uso | |
| BR0303912A (pt) | Composição para o condicionamento, composição para o condicionamento durável, método para o condicionamento, método para o condicionamento durável, método para o cuidado ou tratamento e kit para o cuidado, tratamento, condicionamento ou condicionamento durável | |
| BRPI0410655A (pt) | composição farmacêutica, método de tratar ou prevenir uma infecção pelo vìrus da raiva em um indivìduo em necessidade deste tratamento, vetor de expressão de rhabdovìrus recombinante, célula hospedeira de mamìfero, método de produzir uma anticorpo recombinante humano neutralizante do vìrus da raiva em uma célula de mamìfero, e, uso de uma combinação | |
| CL2022002214A1 (es) | Polipéptidos, composiciones y su uso para tratar o limitar el desarrollo de una infección | |
| WO2021113440A3 (en) | Oligopeptide, testing kit thereof, medical composition thereof and use of medical composition | |
| MX2024001541A (es) | Composiciones proteicas para el tratamiento de enfermedades inflamatorias. |